Anti-tumour necrosis factor (TNF)-a monoclonal antibody therapies can be associated with infectious adverse effects. Although an increased incidence of opportunistic infections including invasive fungal infections is well known, very few cases of dermatophytosis associated with the use of these drugs are reported in the literature (Lee H-H et al., Br J Dermatol 2007; 156: 486–91). We describe here two patients affected by severe psoriasis, without any risk factor that can favour a dermatophytosis, who developed cutaneous mycotic infections caused by Trichophyton spp. under treatment exclusively with anti-TNF-a drugs.
Bardazzi F, Balestri R, Rech G, Antonucci A, Patrizi A. (2011). Dermatophytosis during anti-TNF-alpha monoclonal antibody therapy. MYCOSES, 54, e619-e620 [10.1111/j.1439-0507.2010.01930.x].
Dermatophytosis during anti-TNF-alpha monoclonal antibody therapy.
BARDAZZI, FEDERICO;BALESTRI, RICCARDO;RECH, GIULIA;ANTONUCCI, ANGELA;PATRIZI, ANNALISA
2011
Abstract
Anti-tumour necrosis factor (TNF)-a monoclonal antibody therapies can be associated with infectious adverse effects. Although an increased incidence of opportunistic infections including invasive fungal infections is well known, very few cases of dermatophytosis associated with the use of these drugs are reported in the literature (Lee H-H et al., Br J Dermatol 2007; 156: 486–91). We describe here two patients affected by severe psoriasis, without any risk factor that can favour a dermatophytosis, who developed cutaneous mycotic infections caused by Trichophyton spp. under treatment exclusively with anti-TNF-a drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
